Pretomanid is the second drug approved for drug-resistant TB by the U.S. FDA in more than 40 years, and the first approved as part of a full treatment regimen. It is the first to be developed and registered by a not-for-profit organization.

Fexinidazole is the first all-oral treatment for both stages of T.b. gambiense sleeping sickness, the most common form of the disease. Taken as simple pills for 10 days, fexinidazole presents significant advantages over NECT because it eliminates the need for systematic hospitalization, thus reducing the number of painful lumbar punctures, while strengthening the primary care systems’ ability to accelerate treatment.

In 2018, tafenoquine (TQ; Kozenis/Krintafel) developed through a Medicines for Malaria Venture (MMV) and GlaxoSmithKline (GSK) partnership, became the first new treatment for the prevention of relapse of P. vivax malaria in more than 60 years—and the first-ever single-dose treatment for this indication.

Together, PATH and partners created a new group A meningitis vaccine in record time, navigating rigorous regulatory and technical rules, organizing numerous clinical studies to test the safety and effectiveness of the vaccine, and building local capacity to conduct research and ultimately support product delivery.

Approved by the U.S. Food and Drug Administration (FDA) in 2018, moxidectin is predicted to accelerate elimination of onchocerciasis (better known as “river blindness”) as a global health burden.

FIND and DNDi partnered with the Malaysia Ministry of Health on the Hepatitis C Elimination through Access to Diagnostics (HEAD-Start) project to improve the diagnosis of Hepatitis C (HCV) by making it more affordable and more widely available to those in need, with a focus on serving people coinfected with HIV.

IVI provided hands-on training in fermentation, downstream processing, and quality control to manufacture another OCV. By the following year, a laboratory-scale technology transfer was complete, and by 2014, advanced clinical studies confirmed that Euvichol® was safe and induced an immune response.

The PDP model can be exceptionally nimble. One example of this has been the ability of PDPs, typically dedicated to a single or defined group of diseases, to pivot their expertise and capabilities to contribute to new health challenges, such as the global response to COVID-19. IAVI exemplifies this flexibility as it has translated work on HIV vaccine development to identifying and developing broadly neutralizing antibodies (bnAbs) to combat HIV, COVID-19, and other diseases.

The monthly ring is the first long-acting HIV prevention product and is designed to help address women’s unmet need for new methods given the persistently high rates of HIV they face, especially in Sub-Saharan Africa.

Continued reduction in malaria incidence, morbidity, and mortality by the establishment of a sustainable market for a broader set of ITN tools, which perform in areas of pyrethroid resistance, and have the potential to support insecticide resistance management. begins with an idea.

It all beTo date, EVI has supported the development of approximately 40 different vaccine candidates to early and mid-stage clinical development for a variety of diseases/pathogens, including malaria, leishmaniasis, diarrheal diseases, and emerging infectious diseases.gins with an idea.

Since the early 2000s, Tuberculosis Vaccine Initiative (TBVI) has supported several collaborative research projects for the development of promising TB vaccine candidates. Among the most advanced and most promising new candidates is the MTBVAC TB vaccine.